Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC)

Endocrine

Volumn 49, Issue 1, 2015, Pages 204-214

  Pereira, Joana S ^a,b   da Silva, Joana Gomes ^a,b   Tomaz, Rute Alexandra ^a,b   Pinto, António Evaristo ^a   Bugalho, Maria João ^a   Leite, Valeriano ^a,b   Cavaco, Branca Maria ^a,b  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Clone; Familial non medullary thyroid carcinoma (FNMTC); FOXE1; Pool; Thyroid; Variant

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXE1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL; CELL CULTURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GERMLINE MUTATION; HUMAN; MALE; MIDDLE AGED; PEDIGREE; PORTUGAL; RAT; THYROID TUMOR; YOUNG ADULT;

ADULT; AGED; ANIMALS; CELLS, CULTURED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PEDIGREE; POLYMORPHISM, GENETIC; PORTUGAL; RATS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84938342196     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0470-0     Document Type: Article

References (29)

1. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs (WHO, Lyon, 2004)
2. M. Capezzone, S. Marchisotta, S. Cantara, G. Busonero, L. Brilli, K. Pazaitou-Panayiotou, A.F. Carli, G. Caruso, P. Toti, S. Capitani, A. Pammolli, F. Pacini, Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr. Relat. Cancer 15, 1075–1081 (2008)
3. C.D. Malchoff, D.M. Malchoff, Familial nonmedullary thyroid carcinoma. Cancer Control 13, 106–110 (2006)
4. W. Moses, J. Weng, E. Kebebew, Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 21, 367–371 (2011)
5. T.J. Musholt, P.B. Musholt, T. Petrich, G. Oetting, W.H. Knapp, J. Klempnauer, Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J. Surg. 24, 1409–1417 (2000)
6. R.S. Sippel, N.R. Caron, O.H. Clark, An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J. Surg. 31, 924–933 (2007)
7. V.A. LiVolsi, Z.W. Baloch, Familial thyroid carcinoma: the road less travelled in thyroid pathology. Mini-symposium: endocrine pathology. Diagn. Histopathol. 15(2), 87–94 (2009)
8. I. Landa, M. Robledo, Association studies in thyroid cancer susceptibility: are we on the right track? J. Mol. Endocrinol. 47, R43–R58 (2011)
9. B.M. Cavaco, P.F. Batista, L.G. Sobrinho, V. Leite, Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J. Clin. Endocrinol. Metab. 93, 4426–4430 (2008)
10. H. He, A. Bronisz, S. Liyanarachchi, R. Nagy, W. Li, Y. Huang, K. Akagi, M. Saji, D. Kula, A. Wojcicka, N. Sebastian, B. Wen, Z. Puch, M. Kalemba, E. Stachlewska, M. Czetwertynska, J. Dlugosinska, K. Dymecka, R. Ploski, M. Krawczyk, P.J. Morrison, M.D. Ringel, R.T. Kloos, K. Jazdzewski, D.E. Symer, V.J. Vieland, M. Ostrowski, B. Jarząb, A. de la Chapelle, SRGAP1 Is a Candidate Gene for Papillary Thyroid Carcinoma Susceptibility. J. Clin. Endocrinol. Metab. 98, E973–E980 (2013)
11. T.R. Frio, A. Bahubeshi, C. Kanellopoulou, N. Hamel, M. Niedziela, N. Sabbaghian, C. Pouchet, L. Gilbert, P.K. O’Brien, K. Serfas, P. Broderick, R.S. Houlston, F. Lesueur, E. Bonora, S. Muljo, R.N. Schimke, D. Bouron-Dal Soglio, J. Arseneau, K.A. Schultz, J.R. Priest, V.H. Nguyen, H.R. Harach, D.M. Livingston, W.D. Foulkes, M. Tischkowitz, DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 305, 68–77 (2011)
12. H. Fagman, M. Nilsson, Morphogenetics of early thyroid development. J. Mol. Endocrinol. 46, R33–R42 (2011)
13. S. Kimura, Thyroid-specific transcription factors and their roles in thyroid cancer. J. Thyroid Res. 2011, Article ID 710213 (2011)
14. E.S. Ngan, B.H. Lang, T. Liu, C.K. Shum, M.T. So, D.K. Lau, T.Y. Leon, S.S. Cherny, S.Y. Tsai, C.Y. Lo, U.S. Khoo, P.K. Tam, M.M. Garcia-Barceló, A germline mutation (A339 V) in thyroid transcription factor-1 (TITF-1/NKX2-1) in patients with multinodular goiter and papillary thyroid carcinoma. J. Natl. Cancer Inst. 101, 162–175 (2009)
15. M. Zannini, V. Avantaggiato, E. Biffali, M.I. Arnone, K. Sato, M. Pischetola, B.A. Taylor, S.J. Phillips, A. Simeone, R. Di Lauro, TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. EMBO J. 16, 3185–3197 (1997)
16. M. De Felice, C. Ovitt, E. Biffali, A. Rodriguez-Mallon, C. Arra, K. Anastassiadis, P.E. Macchia, M.G. Mattei, A. Mariano, H. Schöler, V. Macchia, R. Di Lauro, A mouse model for hereditary thyroid dysgenesis and cleft palate. Nat. Genet. 19, 395–398 (1998)
17. M. Katoh, M. Katoh, Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGF beta, and Notch signaling cascades. Int. J. Mol. Med. 23, 763–769 (2009)
18. C. Huang, D. Liu, J. Nakano, S. Ishikawa, K. Kontani, H. Yokomise, M. Ueno, Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor—an expression in non-small-cell lung cancer. J. Clin. Oncol. 23, 8765–8773 (2005)
19. R. Amerongen, C. Fuerer, M. Mizutani, R. Nusse, Wnt5a can both activate and repress Wnt/b-catenin signaling during mouse embryonic development. Dev. Biol. 369, 101–114 (2012)
20. R. Habas, I.B. Dawid, Dishevelled and Wnt signaling: is the nucleus the final frontier? J. Biol. 4, 2 (2005)
21. R.A. Tomaz, I. Sousa, J.G. Silva, C. Santos, M.R. Teixeira, V. Leite, B.M. Cavaco, FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clin. Endocrinol. 77, 926–933 (2012)
22. S. André, A.E. Pinto, C. Laranjeira, M. Quaresma, J. Soares, Male and female breast cancer—differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 74, 323–327 (2007)
23. M. Bullock, E.L. Duncan, C. O’Neill, L. Tacon, M. Sywak, S. Sidhu, L. Delbridge, D. Learoyd, B.G. Robinson, M. Ludgate, R.J. Clifton-Bligh, Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J. Clin. Endocrinol. Metab. 97, E1–E6 (2012)
24. I. Landa, S. Ruiz-Llorente, C. Montero-Conde, L. Inglada-Pérez, F. Schiavi, S. Leskelä, G. Pita, R. Milne, J. Maravall, I. Ramos, V. Andía, P. Rodríguez-Poyo, A. Jara-Albarrán, A. Meoro, C. del Peso, L. Arribas, P. Iglesias, J. Caballero, J. Serrano, A. Picó, F. Pomares, G. Giménez, P. López-Mondéjar, R. Castello, I. Merante-Boschin, M.R. Pelizzo, D. Mauricio, G. Opocher, C. Rodríguez-Antona, A. González-Neira, X. Matías-Guiu, P. Santisteban, M. Robledo, The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 5, e1000637 (2009)
25. R. Kallel, S. Belguith-Maalej, A. Akdi, M. Mnif, I. Charfeddine, P. Galofré, A. Ghorbel, M. Abid, R. Marcos, H. Ayadi, A. Velázquez, Hadj Kacem, H.: Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma. Cancer 8, 43–51 (2010)
26. J. Gudmundsson, P. Sulem, D.F. Gudbjartsson, J.G. Jonasson, A. Sigurdsson, J.T. Bergthorsson, H. He, T. Blondal, F. Geller, M. Jakobsdottir, D.N. Magnusdottir, S. Matthiasdottir, S.N. Stacey, O.B. Skarphedinsson, H. Helgadottir, W. Li, R. Nagy, E. Aguillo, E. Faure, E. Prats, B. Saez, M. Martinez, G.I. Eyjolfsson, U.S. Bjornsdottir, H. Holm, K. Kristjansson, M.L. Frigge, H. Kristvinsson, J.R. Gulcher, T. Jonsson, T. Rafnar, H. Hjartarsson, J.I. Mayordomo, A. de la Chapelle, J. Hrafnkelsson, U. Thorsteinsdottir, A. Kong, K. Stefansson, Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat. Genet. 41, 460–464 (2009)
27. M. Kurayoshi, N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui, A. Kikuchi, Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66, 10439–10448 (2006)
28. N. Kremenevskaja, R. von Wasielewski, A.S. Rao, C. Schöfl, T. Andersson, G. Brabant, Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24, 2144–2154 (2005)
29. B.M. Cavaco, P.F. Batista, C. Martins, A. Banito, F. do Rosario, E. Limbert, L.G. Sobrinho, V. Leite, Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr. Relat. Cancer 15, 207–215 (2008)